Thomson Reuters Corporation : Thomson Reuters Helps Pharmaceutical Executives Identify Drugs with Repositioning Potential
(Thomson Reuters ONE) -
Unique approach uses Thomson Reuters drug data and expert analysis to identify
repositioning candidates
PHILADELPHIA, PA, October 23, 2012 - With more than 2,000 drugs reintroduced for
alternative purposes to date, drug repositioning has become a viable solution
for pharmaceutical companies to generate additional revenue. The Intellectual
Property & Science business of Thomson Reuters, the world's leading provider of
intelligent information for businesses and professionals, provided deeper
insight today into the unique approach its Life Sciences consulting service
takes in analyzing drugs and drug candidates to identify those with potential
for repositioning.
Thomson Reuters has raised the bar in both speed and rigor in drug repositioning
by successfully utilizing multiple data-driven methods connecting its various
data assets that link clinical outcomes to signaling mechanisms. The company
also integrates its unique expertise in orphan and rare disease strategy with
drug repositioning in support of a full life cycle strategy for a drug
candidate. The company's novel approach can reduce trial and error laboratory
testing and shorten the development cycle utilizing proprietary information
combined with scientific expertise to develop repositioning schemes.
"The business of drug repositioning has transformed from the serendipitous
approach of acting on clinical observations to a data-driven and predictive
approach that can identify more repositioning opportunities and direct those
opportunities to more responsive patient segments. These advances have the
potential to change the way pharmaceutical companies deliver value to patients
around the world," said Chris McKenna, vice president of Thomson Reuters Life
Sciences Professional Services. "We've created an information environment and
unique algorithms that our analysts use to perform systematic evaluation of
small and large molecule drug candidates across thousands of diseases in refined
patient segments."
Repositioned drugs tend to enter the market approximately three to five years
faster than conventionally developed drugs, have traditionally higher success
rates, and cost less in R&D when compared to a typical drug development cycle.
According to current estimates, 200 drugs are repositioned annually.
Further information on Thomson Reuters drug repositioning services is available
by downloading "Knowledge-Based Drug Repositioning to Drive R&D Productivity," a
Thomson Reuters white paper or sign up for the Drug Repositioning Webinar on
November 8 from 10am-11am EST. On October 23, Dr. Richard Harrison, Director,
Discovery Practice will give a talk on the topic of drug repositioning at the
Drug Repositioning and Indications Conference in San Francisco.
About Thomson Reuters
Thomson Reuters is the world's leading source of intelligent information for
businesses and professionals. We combine industry expertise with innovative
technology to deliver critical information to leading decision makers in the
financial and risk, legal, tax and accounting, intellectual property and science
and media markets, powered by the world's most trusted news organization. With
headquarters in New York and major operations in London and Eagan, Minnesota,
Thomson Reuters employs approximately 60,000 people and operates in over 100
countries. For more information, go to www.thomsonreuters.com.
CONTACTS
Jen Breen Abbey Anderson
Thomson Reuters Thomson Reuters
+1 215 823 1791 +1 215 823 1894
jennifer.breen(at)thomsonreuters.com abbey.anderson(at)thomsonreuters.com
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Thomson Reuters Corporation via Thomson Reuters ONE
[HUG#1651319]
Unternehmensinformation / Kurzprofil:
Datum: 23.10.2012 - 15:00 Uhr
Sprache: Deutsch
News-ID 195316
Anzahl Zeichen: 4648
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 236 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thomson Reuters Corporation : Thomson Reuters Helps Pharmaceutical Executives Identify Drugs with Repositioning Potential"
steht unter der journalistisch-redaktionellen Verantwortung von
Thomson Reuters Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
